Search results for "Comorbidity Multiple sclerosis Heart failure Mitoxantrone Therapy"

showing 1 items of 1 documents

Cardiovascular comorbidity in multiple sclerosis patients treated with mitoxantrone therapy: a cohort study

2017

Abstract Background Mitoxantrone (MX) has been used as second line therapy for aggressive multiple sclerosis (MS). Potential cardiotoxic effects of MX limit its use; a cumulative dose of up to 100 mg/m2, has been long considered relatively safe. We calculated the frequency of cardiac side effects in MS patients treated with MX. Methods We performed a cohort study including all MS patients treated with MX at the Neurological Department of the University Hospital of Palermo, Italy. Two hundred-sixty-four MS patients diagnosed according to validated criteria were included and followed-up until the end of September 2010. Patients were treated with MX as a second line therapy if they had no prev…

medicine.medical_specialtyImmunologyHeart failureComorbidity030204 cardiovascular system & hematologylcsh:RC346-429Multiple sclerosis03 medical and health sciences0302 clinical medicineInternal medicinemedicineImmunology and AllergyMyocardial infarctionlcsh:Neurology. Diseases of the nervous systemMitoxantroneEjection fractionmedicine.diagnostic_testCumulative dosebusiness.industryComorbidity Multiple sclerosis Heart failure Mitoxantrone Therapymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareNeurologyHeart failureCohortPhysical therapySettore MED/26 - NeurologiaTherapyNeurology (clinical)MitoxantronebusinessElectrocardiography030217 neurology & neurosurgeryCohort studymedicine.drug
researchProduct